Published in Ann Neurol on April 04, 2012
B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol (2012) 1.80
Epitope spreading as an early pathogenic event in pediatric multiple sclerosis. Neurology (2014) 1.43
Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol (2012) 1.41
Node of Ranvier disruption as a cause of neurological diseases. ASN Neuro (2013) 1.01
The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol (2013) 1.01
Extracellular vesicles as modulators of cell-to-cell communication in the healthy and diseased brain. Philos Trans R Soc Lond B Biol Sci (2014) 0.99
Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. Lancet Neurol (2014) 0.85
Clinical relevance of voltage-gated potassium channel–complex antibodies in children. Neurology (2015) 0.85
B Cells and Autoantibodies in Multiple Sclerosis. Int J Mol Sci (2015) 0.83
Pediatric multiple sclerosis: current concepts and consensus definitions. Autoimmune Dis (2013) 0.83
Apoptosis of Oligodendrocytes during Early Development Delays Myelination and Impairs Subsequent Responses to Demyelination. J Neurosci (2015) 0.82
Gray matter is targeted in first-attack multiple sclerosis. PLoS One (2013) 0.82
Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegeneration. PLoS One (2014) 0.79
Gray matter-related proteins are associated with childhood-onset multiple sclerosis. Neurol Neuroimmunol Neuroinflamm (2015) 0.78
Cerebrospinal fluid proteomics: a new window for understanding human demyelinating disorders? Ann Neurol (2012) 0.77
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med (2012) 7.58
Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology (2007) 4.23
Global changes to the ubiquitin system in Huntington's disease. Nature (2007) 3.91
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet (2011) 3.76
Neuronal CA2+/calmodulin-dependent protein kinase II: the role of structure and autoregulation in cellular function. Annu Rev Biochem (2001) 3.64
Structure-function of the multifunctional Ca2+/calmodulin-dependent protein kinase II. Biochem J (2002) 3.29
Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol (2007) 2.68
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med (2007) 2.64
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol (2006) 2.62
CaMKII tethers to L-type Ca2+ channels, establishing a local and dedicated integrator of Ca2+ signals for facilitation. J Cell Biol (2005) 2.47
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler (2010) 2.45
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med (2012) 2.36
Selective regulation of neurite extension and synapse formation by the beta but not the alpha isoform of CaMKII. Neuron (2003) 2.36
International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler (2013) 2.20
Neural and immunological synaptic relations. Science (2002) 2.17
Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander disease. Ann Neurol (2005) 2.16
MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol (2011) 2.12
Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol (2007) 2.07
Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol (2006) 2.06
Transition from reversible to persistent binding of CaMKII to postsynaptic sites and NR2B. J Neurosci (2006) 2.05
The cardiac-specific nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J Biol Chem (2001) 1.99
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol (2011) 1.92
Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol (2004) 1.89
Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol (2007) 1.88
Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol (2010) 1.81
A role for Nr-CAM in the patterning of binocular visual pathways. Neuron (2006) 1.79
A mechanism for Ca2+/calmodulin-dependent protein kinase II clustering at synaptic and nonsynaptic sites based on self-association. J Neurosci (2005) 1.78
Unusual variants of Alexander's disease. Ann Neurol (2005) 1.76
Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med (2014) 1.75
Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci (2013) 1.74
Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol (2007) 1.73
Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia (2012) 1.73
Gamma-protocadherins are targeted to subsets of synapses and intracellular organelles in neurons. J Neurosci (2003) 1.61
Protein standard absolute quantification (PSAQ) method for the measurement of cellular ubiquitin pools. Nat Methods (2011) 1.60
Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest (2003) 1.59
NeuriteTracer: a novel ImageJ plugin for automated quantification of neurite outgrowth. J Neurosci Methods (2007) 1.59
Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol (2008) 1.58
An ultrasensitive Ca2+/calmodulin-dependent protein kinase II-protein phosphatase 1 switch facilitates specificity in postsynaptic calcium signaling. Proc Natl Acad Sci U S A (2003) 1.57
Quantifying reproducibility for differential proteomics: noise analysis for protein liquid chromatography-mass spectrometry of human serum. Bioinformatics (2004) 1.57
A mechanism for tunable autoinhibition in the structure of a human Ca2+/calmodulin- dependent kinase II holoenzyme. Cell (2011) 1.56
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler (2012) 1.55
Glial membranes at the node of Ranvier prevent neurite outgrowth. Science (2005) 1.55
Adhesion molecules in the nervous system: structural insights into function and diversity. Annu Rev Neurosci (2007) 1.52
Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis. Arch Neurol (2010) 1.51
The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported. Pediatrics (2006) 1.50
Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol (2009) 1.50
TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function. J Immunol (2011) 1.47
Differential expression of individual gamma-protocadherins during mouse brain development. Mol Cell Neurosci (2005) 1.46
B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol (2011) 1.45
Rapid method for culturing embryonic neuron-glial cell cocultures. J Neurosci Res (2003) 1.44
Regulation of calcium/calmodulin-dependent protein kinase II docking to N-methyl-D-aspartate receptors by calcium/calmodulin and alpha-actinin. J Biol Chem (2002) 1.44
Risk genes associated with pediatric-onset MS but not with monophasic acquired CNS demyelination. Neurology (2013) 1.44
Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J Neurosci (2005) 1.43
Cadherin activity is required for activity-induced spine remodeling. J Cell Biol (2004) 1.43
Hidden focal EEG seizures during prolonged suppressions and high-amplitude bursts in early infantile epileptic encephalopathy. Clin Neurophysiol (2005) 1.39
Epstein-Barr virus in pediatric multiple sclerosis. JAMA (2004) 1.38
Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase. Blood (2006) 1.36
Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol (2004) 1.34
Quantitative analysis of human endogenous retrovirus-W env in neuroinflammatory diseases. AIDS Res Hum Retroviruses (2006) 1.34
Microglia and multiple sclerosis. J Neurosci Res (2005) 1.34
Chemical quenched flow kinetic studies indicate an intraholoenzyme autophosphorylation mechanism for Ca2+/calmodulin-dependent protein kinase II. J Biol Chem (2002) 1.30
International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum (2007) 1.28
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol (2013) 1.27
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol (2013) 1.27
Rapid assembly of functional presynaptic boutons triggered by adhesive contacts. J Neurosci (2009) 1.26
Alternative splicing modulates the frequency-dependent response of CaMKII to Ca(2+) oscillations. EMBO J (2002) 1.23
Promiscuous protein biotinylation by Escherichia coli biotin protein ligase. Protein Sci (2004) 1.22
Intersubunit capture of regulatory segments is a component of cooperative CaMKII activation. Nat Struct Mol Biol (2010) 1.21
2010 McDonald criteria for diagnosing pediatric multiple sclerosis. Ann Neurol (2012) 1.21
miR-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization. Ann Neurol (2013) 1.21
Petroleum crude oil characterization by IMS-MS and FTICR MS. Anal Chem (2009) 1.21
Neuromyelitis optica with hypothalamic involvement. Mult Scler (2005) 1.20
Determinants of human B cell migration across brain endothelial cells. J Immunol (2003) 1.19
Lesion distribution in children with clinically isolated syndromes. Ann Neurol (2008) 1.17
Ca2+/calmodulin-dependent protein kinase II is required for microcystin-induced apoptosis. J Biol Chem (2001) 1.16
Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol (2003) 1.16
B-cell-derived interleukin-10 in autoimmune disease: regulating the regulators. Nat Rev Immunol (2008) 1.14
Effect of varying feedstock-pretreatment chemistry combinations on the formation and accumulation of potentially inhibitory degradation products in biomass hydrolysates. Biotechnol Bioeng (2010) 1.13
Pediatric central nervous system inflammatory demyelination: acute disseminated encephalomyelitis, clinically isolated syndromes, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol (2009) 1.13
Treatment of multiple sclerosis with anti-CD20 antibodies. Clin Immunol (2011) 1.10
Do myelin-directed antibodies predict multiple sclerosis? N Engl J Med (2003) 1.10
Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. Arch Neurol (2009) 1.10
Byonic: advanced peptide and protein identification software. Curr Protoc Bioinformatics (2012) 1.10
Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J Neuroimmunol (2005) 1.09
Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev (2007) 1.08
Calcium/calmodulin-dependent protein kinase II (CaMKII) localization acts in concert with substrate targeting to create spatial restriction for phosphorylation. J Biol Chem (2004) 1.08
Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. Ann Neurol (2010) 1.08
Magnetic resonance imaging features of the spinal cord in pediatric multiple sclerosis: a preliminary study. Neuroradiology (2010) 1.07
Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J Neuroimmunol (2006) 1.06
Deficiency of asparagine synthetase causes congenital microcephaly and a progressive form of encephalopathy. Neuron (2013) 1.06